BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026

Rhea-AI Summary

BeyondSpring (NASDAQ: BYSI) will present a poster at the AACR Annual Meeting 2026 in San Diego on April 21, 2026. The poster, titled Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates, is scheduled for 2:00–5:00 PM PT in Poster Section 8, Poster Board 16 (Poster 5597).

The presentation appears in the Immunology session category under "T Cell Engagers 2 / Antibody-Drug Conjugates 1" and lists Yingjuan June Lu and colleagues as presenters/authors.

Key Figures

AACR meeting dates: April 17–22, 2026 Presentation date: April 21, 2026 Presentation time: 2 PM–5 PM PT +5 more

8 metrics

AACR meeting dates April 17–22, 2026 AACR Annual Meeting schedule in San Diego

Presentation date April 21, 2026 Plinabulin + ADC poster presentation day

Presentation time 2 PM–5 PM PT Poster session time window

Poster section Section 8 Location within San Diego Convention Center

Poster board number 16 Assigned AACR poster board

Poster number 5597 AACR program poster identifier

Current share price $1.60 Pre-news trading level on publication day

52-week range $0.98–$3.44 52-week low and high before this news

Market Reality Check

Price: $1.6000 Vol: Volume 22,269 is 0.85x th...

normal vol

$1.6000 Last Close

Volume Volume 22,269 is 0.85x the 20-day average, indicating subdued trading ahead of the AACR poster. normal

Technical Shares at $1.60 are trading below the 200-day MA of $1.88 and sit 53.49% under the 52-week high.

Peers on Argus

Sector peers show mixed moves with no broad rotation: IMMX appeared on momentum ...

1 Up

Sector peers show mixed moves with no broad rotation: IMMX appeared on momentum scanners, moving up 7.85%, while other close peers had varied daily changes between roughly -9.14% and 2.17%.

Historical Context

5 past events · Latest: Mar 25 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 25	Annual report filing	Negative	-4.2%	10-K filing detailing continued losses and need for additional capital.
Mar 25	Year-end earnings	Positive	+3.7%	Year-end results highlighting positive Phase 3 plinabulin data and SEED progress.
Feb 09	Conference participation	Neutral	+0.7%	Immuno-Oncology 360° presentation on plinabulin’s mechanism and strategy.
Dec 12	Clinical data update	Positive	-3.2%	ESMO Asia DUBLIN-3 Asian subset showing OS benefit and reduced neutropenia.
Dec 11	Clinical data update	Positive	+7.9%	NACLC analyses showing survival and metastasis benefits post anti-PD-(L)1 therapy.

Pattern Detected

Recent news with positive clinical or strategic content often aligned with price gains, while one positive clinical update drew a negative reaction.

Recent Company History

Over the last six months, BeyondSpring has reported multiple milestones around plinabulin and its oncology pipeline. Positive Phase 3 data and DUBLIN-3/DUBLIN-4 plans in Dec 2025 drove mixed reactions, including one strong gain and one selloff. In Feb 2026, an Immuno-Oncology 360° conference appearance saw a modest uptick. On Mar 25, 2026, 2025 results and the Form 10‑K filing produced a small gain for earnings but a decline for the 10‑K. Today’s AACR poster fits this pattern of ongoing scientific visibility for plinabulin.

Market Pulse Summary

This announcement highlights a scientific poster on plinabulin combined with topoisomerase inhibitor...

Analysis

This announcement highlights a scientific poster on plinabulin combined with topoisomerase inhibitor-based antibody-drug conjugates at the AACR 2026 meeting, reinforcing BeyondSpring’s focus on immuno-oncology combinations. It follows recent positive Phase 3 data and multiple conference presentations on plinabulin. Investors may track future clinical readouts, regulatory interactions and financing developments, especially given the company’s clinical-stage status and prior filings describing operating losses, cash levels and plans for the DUBLIN-4 confirmatory trial.

Key Terms

antibody-drug conjugates, immune checkpoint inhibitor, topoisomerase inhibitor, t cell engagers

4 terms

antibody-drug conjugates medical

"T Cell Engagers 2 / Antibody-Drug Conjugates 1Poster Board Number"

A class of targeted cancer medicines that combine a lab-made antibody (which finds and sticks to specific markers on tumor cells) with a powerful cell-killing drug linked together so the toxic payload is delivered directly to the tumor. Think of it like a guided missile that reduces collateral damage compared with traditional chemotherapy; for investors, success or failure of these drugs drives clinical, regulatory and commercial value and can sharply affect a biotech company’s prospects and stock price.

immune checkpoint inhibitor medical

"Without or With Immune Checkpoint InhibitorPresenter / Authors: Yingjuan"

An immune checkpoint inhibitor is a type of medicine that helps the body's immune system recognize and attack cancer cells more effectively. It works by blocking certain signals that cancer uses to hide from immune defenses, allowing the immune system to target tumors. This breakthrough has led to new cancer treatments, making immune checkpoint inhibitors an important area of growth and innovation in the healthcare industry.

topoisomerase inhibitor medical

"Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates Without"

A topoisomerase inhibitor is a type of drug that blocks certain enzymes called topoisomerases, which help cells untangle and organize their DNA during growth and reproduction. By stopping these enzymes, the drug can prevent cells from dividing and multiplying, making it useful in treatments like cancer therapy. Investors should understand that such drugs can significantly impact pharmaceutical companies' success and healthcare markets.

t cell engagers medical

"Session Title: T Cell Engagers 2 / Antibody-Drug Conjugates 1Poster"

T cell engagers are engineered molecules that act like a matchmaker or bridge, linking a patient’s T cells (immune cells that kill infected or cancerous cells) directly to diseased cells so the immune system can destroy them. For investors, they matter because successful T cell engagers can become high-value therapies with steep clinical and regulatory milestones that drive a biotech company’s revenue potential and share price, while failures or safety issues can rapidly reduce valuation.

AI-generated analysis. Not financial advice.

FLORHAM PARK, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced that the Company will have a poster presentation at the 2026 Annual Meeting of the American Association for Cancer Research ("AACR"), taking place on April 17 through 22, 2026 in San Diego, California.

Presentation Details:

• Title: Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates Without or With Immune Checkpoint Inhibitor
• Presenter / Authors: Yingjuan June Lu, Xiaoyan He, Weiwei Cheng, Zhengyan Zhang, James Tonra, Lan Huang
• Presentation Time: April 21, 2026, 2PM to 5PM PT
• Location: Poster Section 8 at San Diego Convention Center
• Session Category: Immunology
• Session Title: T Cell Engagers 2 / Antibody-Drug Conjugates 1
• Poster Board Number: 16
• Poster Number: 5597

About BeyondSpring
BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies addressing high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC and other indications. Plinabulin’s novel mechanism as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to restoring tumor sensitivity to checkpoint inhibitors. Learn more at https://beyondspringpharma.com.

Investor Contact: IR@beyondspringpharma.com
Media Contact: PR@beyondspringpharma.com

FAQ

When will BeyondSpring (BYSI) present the plinabulin and ADC poster at AACR 2026?

BeyondSpring will present the poster on April 21, 2026 from 2:00–5:00 PM PT. According to the company, the presentation is scheduled in Poster Section 8 at the San Diego Convention Center as Poster Board 16 (Poster 5597).

What is the title of BeyondSpring's (BYSI) AACR 2026 poster on plinabulin and ADCs?

The poster title is Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates. According to the company, the work examines plinabulin combined with ADCs, with or without immune checkpoint inhibitors, in preclinical immunology studies.

Where is BeyondSpring (BYSI) located at AACR 2026 and what is the poster number?

BeyondSpring's poster is located in Poster Section 8, Poster Board 16 and listed as Poster 5597. According to the company, attendees can find the poster at the San Diego Convention Center during the April 21 poster session.

Which session category will BeyondSpring's (BYSI) poster appear in at AACR 2026?

The poster appears under the Immunology session category, specifically "T Cell Engagers 2 / Antibody-Drug Conjugates 1." According to the company, this places the work among presentations focused on immune-engagement and ADC strategies.

Who are the presenters and authors for BeyondSpring's (BYSI) AACR 2026 poster on plinabulin?

The presenter/authors listed include Yingjuan June Lu, Xiaoyan He, Weiwei Cheng, Zhengyan Zhang, James Tonra, and Lan Huang. According to the company, these individuals are credited as the authors and presenter of the poster.

Does BeyondSpring (BYSI) report clinical or financial data in the AACR 2026 poster announcement?

No, the announcement is a conference poster presentation notice and does not include clinical efficacy numbers or financial data. According to the company, the release provides logistical details for the April 21 poster session only.